drugset / Trial / NCT05130255
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Non-randomizedSequentialSingle-blindTreatment
Summary
Patients with Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA) to assess safety and tolerability
Timeline
- Start
- 2022-11-17
- Primary completion
- 2026-03-11
- Completion
- 2026-03-11
Outcome
Outcome not reported
Stopped: “Decision by Sponsor”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-DOTA | Unknown | 1110 mbq | Intravenous |
| Subject | 177Lu-DOTA | Unknown | 3700 mbq | Intravenous |
| Subject | 177Lu-DOTA | Unknown | 7400 mbq | Intravenous |
| Subject | GD2-SADA | Unknown | 0.3 mg/kg | Intravenous |
| Subject | GD2-SADA | Unknown | 1 mg/kg | Intravenous |
| Subject | GD2-SADA | Unknown | 3 mg/kg | Intravenous |